Mostrar el registro sencillo del ítem
dc.contributor.author | Pintér, Dávid | |
dc.contributor.author | Martínez-Martín, Pablo | |
dc.contributor.author | Janszky, József | |
dc.contributor.author | Kovács, Norbert | |
dc.date.accessioned | 2020-03-18T09:48:39Z | |
dc.date.available | 2020-03-18T09:48:39Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Parkinsons Dis. 2019 Sep 10;2019:1412984. | es_ES |
dc.identifier.issn | 2090-8083 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/9273 | |
dc.description.abstract | Background: The Parkinson's Disease Composite Scale (PDCS) is a recently developed easy-to-use tool enabling a timely but comprehensive assessment of Parkinson's disease (PD)-related symptoms. Although the PDCS has been extensively validated, its responsiveness to acute levodopa challenge has not been demonstrated yet. Objective: To investigate the correlation between changes in the motor examination part of the Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the PDCS motor scores during acute levodopa challenge and calculate a cutoff range on the PDCS indicating clinically relevant improvement. Methods: A consecutive series of 100 patients with parkinsonism were assessed using the motor examination sections of the MDS-UPDRS and the PDCS at least 12 hours after the last levodopa dose and after the administration of a single dose of a suprathreshold immediate formulation of levodopa/benserazide reaching the "best ON." Results. There was a high correlation between changes in the MDS-UPDRS and the PDCS motor scores (Spearman's rho = 0.73, p < 0.001). Receiver operating characteristic analysis revealed that a 14.6%-18.5% improvement in the PDCS motor scores corresponds to a 20-30% improvement in the MDS-UPDRS motor examination. Conclusions: The PDCS can reliably and adequately respond to an acute levodopa challenge. Any improvements in PDCS motor scores exceeding the 14.6-18.5% threshold could represent a clinically relevant response to levodopa. | es_ES |
dc.description.sponsorship | This study was supported by the Hungarian Brain Research Program (2017-1.2.1-NKP-2017-00002) and NKFIH (EFOP-3.6.2-16-2017-00008, SNN125143, and ÚNKP-17-4-I.-PTE-311) (government-based funds). Our research was partly financed by the Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary, within the framework of the 5th thematic program of the University of Pécs, Hungary (20765/3/2018/FEKUSTRAT). The authors would like to thank Éva Balázs and Katalin Takács, our Parkinson’s nurses, for their assistance in study-related examinations. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Hindawi | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | The Parkinson's Disease Composite Scale Is Adequately Responsive to Acute Levodopa Challenge | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 31583072 | es_ES |
dc.format.volume | 2019 | es_ES |
dc.format.page | 1412984 | es_ES |
dc.identifier.doi | 10.1155/2019/1412984 | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.1155/2019/1412984 | es_ES |
dc.identifier.journal | Parkinson's disease | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Epidemiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | Info:eu-repo/grantAgreement/2017-1.2.1-NKP-2017-00002 | es_ES |
dc.relation.projectID | Info:eu-repo/grantAgreement/EFOP-3.6.2-16-2017-00008 | es_ES |
dc.relation.projectID | Info:eu-repo/grantAgreement/SNN125143 | es_ES |
dc.relation.projectID | Info:eu-repo/grantAgreement/ÚNKP-17-4-I.-PTE-311 | es_ES |
dc.relation.projectID | Info:eu-repo/grantAgreement/20765/3/2018/FEKUSTRAT | es_ES |
dc.rights.accessRights | open access | es_ES |